Codexis (CDXS) Income from Continuing Operations (2010 - 2026)
Codexis (CDXS) posted quarterly Income from Continuing Operations of 8704000.0 for Q1 2026, up 57.93% year-over-year from 5511396.67 in Q1 2025, and down 190.66% quarter-over-quarter from 9601000.0 in Q4 2025.
Codexis (CDXS) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Codexis' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 8704000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 57.93% year-over-year to 8704000.0; the TTM figure through Mar 2026 stood at 31990000.0 (up 57.04% YoY), while the FY2025 annual figure was 43974000.0, up 32.63% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 8704000.0, down from 9601000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 9601000.0 in Q4 2025, with the low at 34908000.0 in Q3 2023.
- The 5-year median for Income from Continuing Operations is 11523000.0 (2023), against an average of 13399176.47.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations sank 545.28% in 2022, then surged 192.53% in 2025.
- Codexis' Income from Continuing Operations stood at 12604000.0 in 2022, then surged by 42.94% to 7192000.0 in 2023, then plunged by 44.27% to 10376000.0 in 2024, then soared by 192.53% to 9601000.0 in 2025, then tumbled by 190.66% to 8704000.0 in 2026.
- Business Quant data shows CDXS's Income from Continuing Operations at 8704000.0 in Q1 2026, 9601000.0 in Q4 2025, and 19615000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Codexis | 152.06 Mn | 97.14 Mn | 11.40 Mn | -12.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.01 Mn |
| Mar 31, 2026 | -8.70 Mn |
| Dec 31, 2025 | 9.60 Mn |
| Sep 30, 2025 | -19.62 Mn |
| Jun 30, 2025 | -13.27 Mn |
| Mar 31, 2025 | -20.69 Mn |
| Dec 31, 2024 | -10.38 Mn |
| Sep 30, 2024 | -20.64 Mn |
| Jun 30, 2024 | -22.76 Mn |
| Mar 31, 2024 | -11.51 Mn |
| Dec 31, 2023 | -7.19 Mn |
| Sep 30, 2023 | -34.91 Mn |
| Jun 30, 2023 | -11.52 Mn |
| Mar 31, 2023 | -22.62 Mn |
| Dec 31, 2022 | -12.60 Mn |
| Sep 30, 2022 | -9.99 Mn |
| Jun 30, 2022 | -2.64 Mn |
| Mar 31, 2022 | -8.36 Mn |
| Dec 31, 2021 | -10.19 Mn |
| Sep 30, 2021 | 2.24 Mn |